Smartox Biotechnology

Executive Summary

Smartox Biotechnology is a French research and manufacturing company specializing in the investigation of animal venom properties and the production of bioactive peptide toxins. Founded in 2011 and based in Grenoble, France, the company leverages venoms as a source of innovative small molecules for drug discovery, focusing on peptide toxins that target key membrane receptors such as ion channels, GPCRs, and integrins. Smartox offers a comprehensive range of products and services, including screening libraries, custom toxin synthesis, and analytical services, catering to the life sciences community. As a private company, Smartox positions itself at the intersection of venom bioprospecting and drug discovery, providing valuable tools for neuroscience and small molecule research. Smartox's business model revolves around enabling drug discovery through its venom-derived peptide libraries and contract services. The company's unique expertise in venom peptides offers a distinct advantage in uncovering novel modulators of ion channels and GPCRs, which are key targets in neurological and other diseases. While the company remains privately held with no disclosed funding rounds, its steady presence in the biotech ecosystem suggests a sustainable niche. The conviction score of 65 reflects the company's strong specialization but limited visibility and scale. Potential growth drivers include expanding its product portfolio and securing partnerships with pharmaceutical companies that value its unique venom-based discovery platform.

Upcoming Catalysts (preview)

• Q3 2026Launch of Expanded Venom Peptide Library70% success
• TBDStrategic Partnership with Major Pharma for Ion Channel Screening40% success
• TBDExpansion of Custom Synthesis and Analytical Services80% success